

12/04/2021

Dear Requester,

Thank you for your Freedom of Information request.

In accordance with S.1 (1) (a) of the Freedom of Information Act 2000 (FOIA), I can confirm that we do hold the information relevant to your request. FOI 395

You asked:

Response from Luton and Dunstable University Hospital

Q1. Could you please provide the numbers of patients treated in the last 3 months by

the **Dermatology** department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira- 0 Patient
- Adalimumab Biosimilar – 20 Patients
- Apremilast – 12 Patients
- Brodalumab- 0 Patient
- Certolizumab – 0 Patient
- Dimethyl fumarate – 2 patients
- Etanercept - Enbrel- 0 Patient
- Etanercept Biosimilar- 0 Patient
- Guselkumab - 0 Patient
- Infliximab – Remicade- 0 Patient
- Infliximab Biosimilar – 1 Patient
- Ixekizumab – 0 Patient
- Risankizumab- 0 Patient

- Secukinumab – 11 Patients
- Tildrakizumab - 0 Patient
- Ustekinumab – 13 patients

Q2. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira –2 patients
- Adalimumab Biosimilar – 24 patients
- Golimumab – 1 patient
- Infliximab – Remicade – 0 Patient
- Infliximab Biosimilar – 171 Patient
- Tofacitinib- 0 patient
- Ustekinumab – 26 patients
- Vedolizumab – 33 patients

Q3. If possible, could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab – Humira – 0 Patient
- Adalimumab Biosimilar- Pharmacy do not have this data for adalimumab
- Golimumab – 0 patient
- Infliximab – Remicade- 0 Patient
- Infliximab Biosimilar – 38 Patients
- Tofacitinib– 0 Patient
- Ustekinumab – 0 patients
- Vedolizumab – 14 Patients

Response from Bedford Hospital

Q1. Could you please provide the numbers of patients treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira 0
- Adalimumab Biosimilar 10
- Apremilast 9
- Brodalumab 0
- Certolizumab 0
- Dimethyl fumarate 1
- Etanercept – Enbrel 1
- Etanercept Biosimilar 1
- Guselkumab 7
- Infliximab - Remicade 0
- Infliximab Biosimilar 0
- Ixekizumab 1
- Risankizumab 2
- Secukinumab 23
- Tildrakizumab 0
- Ustekinumab 58

Q2. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 3
- Adalimumab Biosimilar 97
- Golimumab 0
- Infliximab – Remicade 1
- Infliximab Biosimilar 77
- Tofacitinib 0
- Ustekinumab 24
- Vedolizumab 37

Q3. If possible, could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab – Humira 2
- Adalimumab Biosimilar 26
- Golimumab 0
- Infliximab – Remicade 0
- Infliximab Biosimilar 23
- Tofacitinib 0
- Ustekinumab 2
- Vedolizumab 22

If you are not satisfied with the Trust review under the Freedom of Information Act 2000 you may apply directly to the Information Commissioners Officer (ICO) for a review of your appeal decision. The ICO can be contacted at: ICO, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF www.ico.org.uk

Yours sincerely,

IG/FOI Coordinator

This information is provided for your personal use and is the property of Bedfordshire Hospitals NHS Trust and subject to any existing Intellectual Property and Database Rights. Any commercial application or use of this information may be subject to the provisions of the Re-use of Public Sector Information Regulations 2015 (RPSI). This means that if you wish to re-use the information provided for commercial purposes for any reason you must ask the Trust for permission to do so.

Please note that the Trust has a formal internal review and complaints process which is managed by the Information Governance Manager/Data Protection Officer. Should you have any concerns with our response, you can make a formal request for an internal review. Requests *for internal review* should be submitted within three months of the date of receipt of the response to your original letter, and should be addressed to: dataprotectionofficer@ldh.nhs.uk